Compare FLGT & QD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FLGT | QD |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 697.3M | 807.5M |
| IPO Year | 2016 | 2017 |
| Metric | FLGT | QD |
|---|---|---|
| Price | $27.16 | $4.05 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $28.33 | N/A |
| AVG Volume (30 Days) | 272.3K | ★ 310.9K |
| Earning Date | 11-07-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2364.38 |
| EPS | N/A | ★ 0.67 |
| Revenue | ★ $315,549,000.00 | $12,647,260.00 |
| Revenue This Year | $16.84 | N/A |
| Revenue Next Year | $9.74 | N/A |
| P/E Ratio | ★ N/A | $6.13 |
| Revenue Growth | ★ 13.61 | N/A |
| 52 Week Low | $14.57 | $2.04 |
| 52 Week High | $31.04 | $5.08 |
| Indicator | FLGT | QD |
|---|---|---|
| Relative Strength Index (RSI) | 47.00 | 36.04 |
| Support Level | $26.69 | $3.89 |
| Resistance Level | $31.04 | $4.91 |
| Average True Range (ATR) | 0.77 | 0.20 |
| MACD | -0.46 | -0.10 |
| Stochastic Oscillator | 10.80 | 18.63 |
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Qudian Inc is a consumer-oriented technology company engaged in the operation of online platforms to provide small consumer credit products in the People's Republic of China. It aims to empower financial institutions with its technological capabilities, help them improve marketing and operating efficiency, and enable financial institutions to efficiently connect their diversified financial products with scene traffic across the entire network It derives a majority of its revenue from the People's Republic of China.